BQ.1.1, XBB.1, and XBB.1.5 neutralization after bivalent mRNA COVID-19 booster in patients with cancer

Sidse Ehmsen; Rune M Pedersen; Line L Bang; Anders Asmussen; Amalie Kragh; Dorte K Holm; Thomas V Sydenham; Thøger G Jensen; Stefan S Jeppesen; Henrik Frederiksen; Thomas E Andersen; Henrik J Ditzel

doi:10.1016/j.ccell.2023.02.003

BQ.1.1, XBB.1, and XBB.1.5 neutralization after bivalent mRNA COVID-19 booster in patients with cancer

Sidse Ehmsen, Rune M Pedersen, Line L Bang, Anders Asmussen, Amalie Kragh, Dorte K Holm, Thomas V Sydenham, Thøger G Jensen, Stefan S Jeppesen, Henrik Frederiksen, Thomas E Andersen, Henrik J Ditzel^*

^*Corresponding author for this work

Research output: Contribution to journal › Journal article › Research › peer-review

Abstract

Ehmsen et al. evaluate the neutralizing capacity to current SARS-CoV-2 variants in patients with cancer before and after receiving the BNT162b2 bivalent mRNA vaccine booster. Bivalent vaccine provides some protection against BQ.1.1 but fails to protect against XBB.1 and XBB.1.5 in patients with cancer.

Original language	English
Journal	Cancer Cell
Volume	41
Issue number	4
Pages (from-to)	649-650
ISSN	1535-6108
DOIs	https://doi.org/10.1016/j.ccell.2023.02.003
Publication status	Published - 10. Apr 2023

Keywords

BNT162 Vaccine
COVID-19/prevention & control
Humans
Neoplasms/genetics
RNA, Messenger/genetics
SARS-CoV-2/genetics

Documents & Links

10.1016/j.ccell.2023.02.003

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9910012/pdf/main.pdf

SDU Link

Check access to the material in SDU Library's search engine

Cite this

@article{f3fd27986f784496bbb9e3ab13e43580,

title = "BQ.1.1, XBB.1, and XBB.1.5 neutralization after bivalent mRNA COVID-19 booster in patients with cancer",

abstract = "Ehmsen et al. evaluate the neutralizing capacity to current SARS-CoV-2 variants in patients with cancer before and after receiving the BNT162b2 bivalent mRNA vaccine booster. Bivalent vaccine provides some protection against BQ.1.1 but fails to protect against XBB.1 and XBB.1.5 in patients with cancer.",

keywords = "BNT162 Vaccine, COVID-19/prevention & control, Humans, Neoplasms/genetics, RNA, Messenger/genetics, SARS-CoV-2/genetics",

author = "Sidse Ehmsen and Pedersen, {Rune M} and Bang, {Line L} and Anders Asmussen and Amalie Kragh and Holm, {Dorte K} and Sydenham, {Thomas V} and Jensen, {Th{\o}ger G} and Jeppesen, {Stefan S} and Henrik Frederiksen and Andersen, {Thomas E} and Ditzel, {Henrik J}",

year = "2023",

month = apr,

day = "10",

doi = "10.1016/j.ccell.2023.02.003",

language = "English",

volume = "41",

pages = "649--650",

journal = "Cancer Cell",

issn = "1535-6108",

publisher = "Cell Press",

number = "4",

}

TY - JOUR

T1 - BQ.1.1, XBB.1, and XBB.1.5 neutralization after bivalent mRNA COVID-19 booster in patients with cancer

AU - Ehmsen, Sidse

AU - Pedersen, Rune M

AU - Bang, Line L

AU - Asmussen, Anders

AU - Kragh, Amalie

AU - Holm, Dorte K

AU - Sydenham, Thomas V

AU - Jensen, Thøger G

AU - Jeppesen, Stefan S

AU - Frederiksen, Henrik

AU - Andersen, Thomas E

AU - Ditzel, Henrik J

PY - 2023/4/10

Y1 - 2023/4/10

N2 - Ehmsen et al. evaluate the neutralizing capacity to current SARS-CoV-2 variants in patients with cancer before and after receiving the BNT162b2 bivalent mRNA vaccine booster. Bivalent vaccine provides some protection against BQ.1.1 but fails to protect against XBB.1 and XBB.1.5 in patients with cancer.

AB - Ehmsen et al. evaluate the neutralizing capacity to current SARS-CoV-2 variants in patients with cancer before and after receiving the BNT162b2 bivalent mRNA vaccine booster. Bivalent vaccine provides some protection against BQ.1.1 but fails to protect against XBB.1 and XBB.1.5 in patients with cancer.

KW - BNT162 Vaccine

KW - COVID-19/prevention & control

KW - Humans

KW - Neoplasms/genetics

KW - RNA, Messenger/genetics

KW - SARS-CoV-2/genetics

U2 - 10.1016/j.ccell.2023.02.003

DO - 10.1016/j.ccell.2023.02.003

M3 - Journal article

C2 - 36804967

SN - 1535-6108

VL - 41

SP - 649

EP - 650

JO - Cancer Cell

JF - Cancer Cell

IS - 4

ER -

BQ.1.1, XBB.1, and XBB.1.5 neutralization after bivalent mRNA COVID-19 booster in patients with cancer

Abstract

Keywords

Documents & Links

SDU Link

Fingerprint

Cite this